Robin Lewis Jones

**Please do not contact me via DM with clinical or professional queries - contact my PA at sarcoma.medsecchelsea@rmh.nhs.uk**

Japanese researchers found that pressing a specific point on your wrist for 60 seconds before sleep reduces cortisol by 34% and cuts the time to fall asleep in half. It's been used in Japanese hospitals for 40 years. It was never introduced to Western medicine. Read till end 🪡

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26 May 29 - June 2 | Chicago Which trial are you watching most closely? 🌟 PLENARY GAME-CHANGERS 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer 2️⃣ LIBRETTO-432 Adjuvant selpercatinib in RET+ NSCLC 3️⃣ HARMONi-6 Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC 4️⃣ RASolute 302 Daraxonrasib (RMC-6236) in metastatic pancreatic cancer 5️⃣ SARC041 Abemaciclib in dedifferentiated liposarcoma ⚡ FRONTLINE & PERIOPERATIVE SHIFTS 6️⃣ KEYNOTE-B15 / EV-304 EV + pembrolizumab vs chemo in MIBC 7️⃣ LITESPARK-022 Pembrolizumab + belzutifan in adjuvant ccRCC 8️⃣ AMBITION Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer 9️⃣ NeoADAURA Neoadjuvant osimertinib in EGFR+ NSCLC 🔟 A-DREAM ADT interruption strategies in mCSPC 🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY 1️⃣1️⃣ DESTINY-Breast06 T-DXd expands into HER2-ultralow disease 1️⃣2️⃣ CROWN (7-year update) Lorlatinib durability in ALK+ NSCLC 1️⃣3️⃣ DeLLphi-312 Tarlatamab in frontline SCLC 1️⃣4️⃣ COMMIT Atezolizumab + FOLFOX/Bev in MSI-H mCRC 1️⃣5️⃣ IMvigor011 ctDNA-guided adjuvant atezolizumab in bladder cancer #OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

I had the honor of presenting sarcoma treatment updates at the #PRIMO by @OnvivCompany conference this week. So many exciting advances over the past few years! Great to be able to highlight the trials @fredhutch has to offer #sarcoma patients too.

OncoDaily together with US WorldMeds (@USWorldMeds), is happy to introduce Dr. Robin Jones (@RobinL_Jones), who will be a speaker during OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition. Robin Jones is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle. His main research interest focuses on clinical trials and translational research in sarcomas. 🗓 Friday, May 29, 2026 🕒15:30 – 17:30 (EST) 📍Chicago Register here: forms.gle/i1RCDLtQXiqm8Z… #OncoDailyGrandRoundsSarcoma #Sarcoma @ASCO

@knowiiiedge Preposition

People often ask how breakthroughs occur in cancer biology-often the story is more complex - the survival plot for myeloma outcomes is extraordinary - improvements come about in incremental steps - in my lifetime treatment of Myeloma has almost transformed into a curable disease

@ShaunLintern You should read this short book full of truth about the destruction of the Medical Profession in the UK. The result is very disgruntled Junior and Senior Doctors and pay is the compensation they can seek.

💛 July is Sarcoma Awareness Month 💛 Here’s how YOU can help: ✔️ Learn the signs and symptoms ✔️ Share this post ✔️ Support a patient or caregiver Together, we can make a difference. @SarcomaEast @Sarcoma_UK @NHSNotts @NHSDDICB @NHS_LLR @NHSLincsICB

EU approves vimseltinib for the treatment of adult patients with symptomatic #TGCT - the first medication approved by the EU @Deciphera 👏🏻👏🏻👏🏻👏🏻👏🏻 deciphera.com/news/deciphera…

Good work @stern_sydney Need to spread the word @SarcomaEast @BritOrthoOnc @EastleyNick @MrJDStevenson

We’re proud to share the UK TGCT Consensus Guidelines are now live on Bone & Joint Open, alongside a patient-friendly version on our site. Thank you to @BoneJointOpen and all the authors! Medical: boneandjoint.org.uk/Article/10.130…
Patient: tgctsupport.org/uploads/1/3/5/…

We are thrilled to welcome Adrian Ibañez Navarro to the #Orthopaedic Oncology Surgery Unit and the MDT #Sarcoma Unit at @HospiLaPaz . Adrian joins us yesterday, as 8th Clinical Fellow he will be working in close collaboration with current clinical fellow Juan Luis Solano

@ElinardouHelena @DrSanjayPopat @APassaroMD @myESMO @IASLC @OncoAlert We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/helena-…

Reconnecting With Global Lung Cancer Colleagues at ELCC 2026 - Herbert Loong @herbloong @myESMO oncodaily.com/voices/herbert… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

Build a stronger chest with these 4 simple changes

This is such a good listen with so much ground covered - including a lot of questions from our EGFR+ #lungcancer community and @Team_HASAG too. Can’t thank you enough for taking the time to answer so throughly and thoughtfully @DrSanjayPopat 🙏 Listen here podcasts.apple.com/gb/podcast/bre…

It’s nice to get away from #hustle&bussle of didactics presented during the @myESMO @IASLC meeting and spend a couple of minutes perusing through the posters. Always a wonderful place to seek out new ideas and to build solid #futurecollaborations 💡. @CUHKMedicine @apoddc @APCLC_2023 #drugdevelopment

Gloria Marquina invites you to the CTOS Spring Webinar 2026! Details and registration: ctos.org/EducationalPro…

Fred Hutch has built a robust portfolio of targeted therapies for lung cancer, but the next challenge is bigger: helping patients without oncogene‑driven or immunotherapy‑sensitive disease. 🎧 @PGrivasMDPhD's full conversation with Dr. Christina Baik: bit.ly/4cS2JYA

Honored to Receive The ESMO Merit Award - Amalya Sargsyan @amalsargsyan @myESMO oncodaily.com/voices/amalya-… #OncoDaily #Oncology #Cancer #Health #Medicine #Sarcoma #CancerResearch #MedX #MedTwitter